Titre : Vibrionaceae

Vibrionaceae : Questions médicales fréquentes

Termes MeSH sélectionnés :

Tobacco Use Cessation Devices

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une infection par Vibrionaceae ?

Le diagnostic se fait par culture bactérienne à partir d'échantillons de selles.
Infections bactériennes Culture bactérienne
#2

Quels tests sont utilisés pour identifier Vibrio cholerae ?

Des tests biochimiques et des méthodes moléculaires comme la PCR sont utilisés.
Vibrio cholerae PCR
#3

Les tests sérologiques sont-ils utiles pour Vibrionaceae ?

Ils ne sont généralement pas utilisés pour le diagnostic des infections vibrioniques.
Tests sérologiques Infections bactériennes
#4

Quels symptômes indiquent une infection vibrionique ?

Des symptômes comme la diarrhée, les vomissements et la déshydratation peuvent indiquer une infection.
Diarrhée Déshydratation
#5

Comment différencier Vibrionaceae d'autres bactéries ?

L'analyse des caractéristiques morphologiques et des tests biochimiques aide à la différenciation.
Caractéristiques morphologiques Tests biochimiques

Symptômes 5

#1

Quels sont les symptômes courants d'une infection par Vibrionaceae ?

Les symptômes incluent diarrhée aqueuse, crampes abdominales et fièvre.
Diarrhée Fièvre
#2

Les infections vibrioniques causent-elles des vomissements ?

Oui, les vomissements sont fréquents, surtout dans les cas de choléra.
Vomissements Choléra
#3

Y a-t-il des symptômes graves associés aux Vibrionaceae ?

Des symptômes graves incluent la déshydratation sévère et le choc hypovolémique.
Déshydratation Choc hypovolémique
#4

Les symptômes apparaissent-ils rapidement après infection ?

Oui, les symptômes peuvent apparaître rapidement, souvent dans les 24 heures.
Infection Symptômes
#5

Les infections vibrioniques peuvent-elles être asymptomatiques ?

Oui, certaines infections peuvent être asymptomatiques, surtout chez les porteurs sains.
Infections asymptomatiques Porteurs sains

Prévention 5

#1

Comment prévenir les infections par Vibrionaceae ?

La prévention passe par une bonne hygiène, la cuisson des aliments et l'eau potable.
Hygiène Eau potable
#2

Les vaccins existent-ils contre Vibrionaceae ?

Un vaccin contre le choléra est disponible, mais pas pour toutes les espèces de Vibrionaceae.
Vaccins Choléra
#3

Quelles mesures de sécurité alimentaire sont recommandées ?

Il est conseillé de bien cuire les fruits de mer et de ne pas consommer d'eau non traitée.
Sécurité alimentaire Fruits de mer
#4

Les voyageurs doivent-ils prendre des précautions ?

Oui, les voyageurs vers des zones à risque doivent être prudents avec l'eau et la nourriture.
Voyage Précautions sanitaires
#5

L'hygiène des mains est-elle importante ?

Oui, se laver les mains régulièrement est crucial pour prévenir les infections.
Hygiène des mains Prévention des infections

Traitements 5

#1

Quel est le traitement principal pour les infections par Vibrionaceae ?

La réhydratation orale ou intraveineuse est le traitement principal, surtout pour le choléra.
Réhydratation Choléra
#2

Les antibiotiques sont-ils nécessaires pour traiter Vibrionaceae ?

Les antibiotiques peuvent être prescrits dans les cas graves, mais ne sont pas toujours nécessaires.
Antibiotiques Infections bactériennes
#3

Comment prévenir la déshydratation dans les infections vibrioniques ?

L'administration rapide de solutions de réhydratation est essentielle pour prévenir la déshydratation.
Solutions de réhydratation Déshydratation
#4

Les traitements symptomatiques sont-ils efficaces ?

Oui, les traitements symptomatiques comme les antiémétiques peuvent aider à soulager les symptômes.
Traitements symptomatiques Antiémétiques
#5

Y a-t-il des traitements spécifiques pour le choléra ?

Oui, des antibiotiques spécifiques et des solutions de réhydratation sont recommandés.
Choléra Antibiotiques

Complications 5

#1

Quelles complications peuvent survenir avec Vibrionaceae ?

Des complications incluent la déshydratation sévère, le choc et l'insuffisance rénale.
Déshydratation Insuffisance rénale
#2

Le choléra peut-il entraîner des complications graves ?

Oui, le choléra peut entraîner des complications graves comme le choc hypovolémique.
Choléra Choc hypovolémique
#3

Les infections vibrioniques peuvent-elles être mortelles ?

Oui, sans traitement approprié, les infections peuvent être mortelles, surtout chez les vulnérables.
Infections mortelles Vulnérabilité
#4

Comment les complications sont-elles gérées ?

Les complications sont gérées par une réhydratation rapide et un traitement médical approprié.
Gestion des complications Réhydratation
#5

Les personnes âgées sont-elles plus à risque de complications ?

Oui, les personnes âgées sont plus susceptibles de développer des complications graves.
Personnes âgées Complications

Facteurs de risque 5

#1

Quels sont les principaux facteurs de risque d'infection ?

Les principaux facteurs incluent la consommation de fruits de mer crus et l'eau contaminée.
Fruits de mer Eau contaminée
#2

Les personnes immunodéprimées sont-elles à risque ?

Oui, les personnes immunodéprimées courent un risque accru d'infections graves.
Immunodépression Infections graves
#3

Le climat influence-t-il le risque d'infection ?

Oui, les infections par Vibrionaceae sont plus fréquentes dans les climats chauds et humides.
Climat Infections bactériennes
#4

Les enfants sont-ils plus vulnérables ?

Oui, les enfants peuvent être plus vulnérables aux infections et à leurs complications.
Enfants Vulnérabilité
#5

Les voyages dans certaines régions augmentent-ils le risque ?

Oui, voyager dans des régions à risque augmente la probabilité d'infection par Vibrionaceae.
Voyages Risque d'infection
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vibrionaceae : Questions médicales les plus fréquentes", "headline": "Vibrionaceae : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vibrionaceae : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-17", "dateModified": "2025-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vibrionaceae" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Gammaproteobacteria", "url": "https://questionsmedicales.fr/mesh/D020563", "about": { "@type": "MedicalCondition", "name": "Gammaproteobacteria", "code": { "@type": "MedicalCode", "code": "D020563", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Aliivibrio", "alternateName": "Aliivibrio", "url": "https://questionsmedicales.fr/mesh/D059706", "about": { "@type": "MedicalCondition", "name": "Aliivibrio", "code": { "@type": "MedicalCode", "code": "D059706", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.050" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Aliivibrio fischeri", "alternateName": "Aliivibrio fischeri", "url": "https://questionsmedicales.fr/mesh/D048908", "about": { "@type": "MedicalCondition", "name": "Aliivibrio fischeri", "code": { "@type": "MedicalCode", "code": "D048908", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.050.860" } } }, { "@type": "MedicalWebPage", "name": "Aliivibrio salmonicida", "alternateName": "Aliivibrio salmonicida", "url": "https://questionsmedicales.fr/mesh/D044165", "about": { "@type": "MedicalCondition", "name": "Aliivibrio salmonicida", "code": { "@type": "MedicalCode", "code": "D044165", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.050.930" } } } ] }, { "@type": "MedicalWebPage", "name": "Listonella", "alternateName": "Listonella", "url": "https://questionsmedicales.fr/mesh/D053526", "about": { "@type": "MedicalCondition", "name": "Listonella", "code": { "@type": "MedicalCode", "code": "D053526", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.500" } } }, { "@type": "MedicalWebPage", "name": "Photobacterium", "alternateName": "Photobacterium", "url": "https://questionsmedicales.fr/mesh/D010776", "about": { "@type": "MedicalCondition", "name": "Photobacterium", "code": { "@type": "MedicalCode", "code": "D010776", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.590" } } }, { "@type": "MedicalWebPage", "name": "Vibrio", "alternateName": "Vibrio", "url": "https://questionsmedicales.fr/mesh/D014733", "about": { "@type": "MedicalCondition", "name": "Vibrio", "code": { "@type": "MedicalCode", "code": "D014733", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vibrio alginolyticus", "alternateName": "Vibrio alginolyticus", "url": "https://questionsmedicales.fr/mesh/D044149", "about": { "@type": "MedicalCondition", "name": "Vibrio alginolyticus", "code": { "@type": "MedicalCode", "code": "D044149", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.030" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae", "alternateName": "Vibrio cholerae", "url": "https://questionsmedicales.fr/mesh/D014734", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae", "code": { "@type": "MedicalCode", "code": "D014734", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vibrio cholerae non-O1", "alternateName": "Vibrio cholerae non-O1", "url": "https://questionsmedicales.fr/mesh/D044163", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae non-O1", "code": { "@type": "MedicalCode", "code": "D044163", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.075" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O1", "alternateName": "Vibrio cholerae O1", "url": "https://questionsmedicales.fr/mesh/D041241", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O1", "code": { "@type": "MedicalCode", "code": "D041241", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.151" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O139", "alternateName": "Vibrio cholerae O139", "url": "https://questionsmedicales.fr/mesh/D041242", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O139", "code": { "@type": "MedicalCode", "code": "D041242", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae non-O1", "alternateName": "Vibrio cholerae non-O1", "url": "https://questionsmedicales.fr/mesh/D044163", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae non-O1", "code": { "@type": "MedicalCode", "code": "D044163", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.075" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O1", "alternateName": "Vibrio cholerae O1", "url": "https://questionsmedicales.fr/mesh/D041241", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O1", "code": { "@type": "MedicalCode", "code": "D041241", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.151" } } }, { "@type": "MedicalWebPage", "name": "Vibrio cholerae O139", "alternateName": "Vibrio cholerae O139", "url": "https://questionsmedicales.fr/mesh/D041242", "about": { "@type": "MedicalCondition", "name": "Vibrio cholerae O139", "code": { "@type": "MedicalCode", "code": "D041242", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.100.200" } } }, { "@type": "MedicalWebPage", "name": "Vibrio mimicus", "alternateName": "Vibrio mimicus", "url": "https://questionsmedicales.fr/mesh/D044164", "about": { "@type": "MedicalCondition", "name": "Vibrio mimicus", "code": { "@type": "MedicalCode", "code": "D044164", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.500" } } }, { "@type": "MedicalWebPage", "name": "Vibrio parahaemolyticus", "alternateName": "Vibrio parahaemolyticus", "url": "https://questionsmedicales.fr/mesh/D014736", "about": { "@type": "MedicalCondition", "name": "Vibrio parahaemolyticus", "code": { "@type": "MedicalCode", "code": "D014736", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.590" } } }, { "@type": "MedicalWebPage", "name": "Vibrio vulnificus", "alternateName": "Vibrio vulnificus", "url": "https://questionsmedicales.fr/mesh/D041261", "about": { "@type": "MedicalCondition", "name": "Vibrio vulnificus", "code": { "@type": "MedicalCode", "code": "D041261", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B03.660.250.830.830.900" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Vibrionaceae", "alternateName": "Vibrionaceae", "code": { "@type": "MedicalCode", "code": "D014737", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Chunqi Jiang", "url": "https://questionsmedicales.fr/author/Chunqi%20Jiang", "affiliation": { "@type": "Organization", "name": "Laboratory of Microbiology, Faculty of Fisheries Sciences, Hokkaido University, Hakodate, Japan." } }, { "@type": "Person", "name": "Sayaka Mino", "url": "https://questionsmedicales.fr/author/Sayaka%20Mino", "affiliation": { "@type": "Organization", "name": "Laboratory of Microbiology, Faculty of Fisheries Sciences, Hokkaido University, Hakodate, Japan." } }, { "@type": "Person", "name": "Jesús L Romalde", "url": "https://questionsmedicales.fr/author/Jes%C3%BAs%20L%20Romalde", "affiliation": { "@type": "Organization", "name": "Departamento de Microbiología y Parasitología, CRETUS & CIBUS-Facultad de Biología, Universidade de Santiago de Compostela, Campus Vida, Santiago de Compostela, España." } }, { "@type": "Person", "name": "Tomoo Sawabe", "url": "https://questionsmedicales.fr/author/Tomoo%20Sawabe", "affiliation": { "@type": "Organization", "name": "Laboratory of Microbiology, Faculty of Fisheries Sciences, Hokkaido University, Hakodate, Japan. sawabe@fish.hokudai.ac.jp." } }, { "@type": "Person", "name": "William Soto", "url": "https://questionsmedicales.fr/author/William%20Soto", "affiliation": { "@type": "Organization", "name": "Integrated Science Center Rm 3035, Department of Biology, College of William & Mary, 540 Landrum Dr., Williamsburg, VA 23185, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Predictors of Cessation in Men Using a Tobacco Quitline: A Follow-Up Study.", "datePublished": "2023-06-09", "url": "https://questionsmedicales.fr/article/37302515", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.amepre.2023.06.004" } }, { "@type": "ScholarlyArticle", "name": "Smoking cessation patterns, usefulness of quitting methods, and tobacco cessation motivators and barriers to quit in patients with rheumatoid arthritis.", "datePublished": "2023-04-24", "url": "https://questionsmedicales.fr/article/37093403", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10067-023-06593-w" } }, { "@type": "ScholarlyArticle", "name": "A Clinical Decision Support System for Motivational Messaging and Tobacco Cessation Treatment for Parents: Pilot Evaluation of Use and Acceptance.", "datePublished": "2023-03-27", "url": "https://questionsmedicales.fr/article/36972687", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/a-2062-9627" } }, { "@type": "ScholarlyArticle", "name": "Economic Evaluation of Enhanced vs Standard Varenicline Treatment for Tobacco Cessation.", "datePublished": "2024-04-01", "url": "https://questionsmedicales.fr/article/38683609", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2024.8727" } }, { "@type": "ScholarlyArticle", "name": "Understanding Hesitation to Use Nicotine Replacement Therapy: A Content Analysis of Posts in Online Tobacco-Cessation Support Groups.", "datePublished": "2022-07-11", "url": "https://questionsmedicales.fr/article/35817548", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/08901171221113835" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Bactéries", "item": "https://questionsmedicales.fr/mesh/D001419" }, { "@type": "ListItem", "position": 3, "name": "Proteobacteria", "item": "https://questionsmedicales.fr/mesh/D020560" }, { "@type": "ListItem", "position": 4, "name": "Gammaproteobacteria", "item": "https://questionsmedicales.fr/mesh/D020563" }, { "@type": "ListItem", "position": 5, "name": "Vibrionaceae", "item": "https://questionsmedicales.fr/mesh/D014737" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vibrionaceae - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vibrionaceae", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vibrionaceae", "description": "Comment diagnostiquer une infection par Vibrionaceae ?\nQuels tests sont utilisés pour identifier Vibrio cholerae ?\nLes tests sérologiques sont-ils utiles pour Vibrionaceae ?\nQuels symptômes indiquent une infection vibrionique ?\nComment différencier Vibrionaceae d'autres bactéries ?", "url": "https://questionsmedicales.fr/mesh/D014737?mesh_terms=Tobacco+Use+Cessation+Devices#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vibrionaceae", "description": "Quels sont les symptômes courants d'une infection par Vibrionaceae ?\nLes infections vibrioniques causent-elles des vomissements ?\nY a-t-il des symptômes graves associés aux Vibrionaceae ?\nLes symptômes apparaissent-ils rapidement après infection ?\nLes infections vibrioniques peuvent-elles être asymptomatiques ?", "url": "https://questionsmedicales.fr/mesh/D014737?mesh_terms=Tobacco+Use+Cessation+Devices#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vibrionaceae", "description": "Comment prévenir les infections par Vibrionaceae ?\nLes vaccins existent-ils contre Vibrionaceae ?\nQuelles mesures de sécurité alimentaire sont recommandées ?\nLes voyageurs doivent-ils prendre des précautions ?\nL'hygiène des mains est-elle importante ?", "url": "https://questionsmedicales.fr/mesh/D014737?mesh_terms=Tobacco+Use+Cessation+Devices#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vibrionaceae", "description": "Quel est le traitement principal pour les infections par Vibrionaceae ?\nLes antibiotiques sont-ils nécessaires pour traiter Vibrionaceae ?\nComment prévenir la déshydratation dans les infections vibrioniques ?\nLes traitements symptomatiques sont-ils efficaces ?\nY a-t-il des traitements spécifiques pour le choléra ?", "url": "https://questionsmedicales.fr/mesh/D014737?mesh_terms=Tobacco+Use+Cessation+Devices#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vibrionaceae", "description": "Quelles complications peuvent survenir avec Vibrionaceae ?\nLe choléra peut-il entraîner des complications graves ?\nLes infections vibrioniques peuvent-elles être mortelles ?\nComment les complications sont-elles gérées ?\nLes personnes âgées sont-elles plus à risque de complications ?", "url": "https://questionsmedicales.fr/mesh/D014737?mesh_terms=Tobacco+Use+Cessation+Devices#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vibrionaceae", "description": "Quels sont les principaux facteurs de risque d'infection ?\nLes personnes immunodéprimées sont-elles à risque ?\nLe climat influence-t-il le risque d'infection ?\nLes enfants sont-ils plus vulnérables ?\nLes voyages dans certaines régions augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D014737?mesh_terms=Tobacco+Use+Cessation+Devices#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par Vibrionaceae ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par culture bactérienne à partir d'échantillons de selles." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour identifier Vibrio cholerae ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques et des méthodes moléculaires comme la PCR sont utilisés." } }, { "@type": "Question", "name": "Les tests sérologiques sont-ils utiles pour Vibrionaceae ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Ils ne sont généralement pas utilisés pour le diagnostic des infections vibrioniques." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection vibrionique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la diarrhée, les vomissements et la déshydratation peuvent indiquer une infection." } }, { "@type": "Question", "name": "Comment différencier Vibrionaceae d'autres bactéries ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse des caractéristiques morphologiques et des tests biochimiques aide à la différenciation." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une infection par Vibrionaceae ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent diarrhée aqueuse, crampes abdominales et fièvre." } }, { "@type": "Question", "name": "Les infections vibrioniques causent-elles des vomissements ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vomissements sont fréquents, surtout dans les cas de choléra." } }, { "@type": "Question", "name": "Y a-t-il des symptômes graves associés aux Vibrionaceae ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes graves incluent la déshydratation sévère et le choc hypovolémique." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils rapidement après infection ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent apparaître rapidement, souvent dans les 24 heures." } }, { "@type": "Question", "name": "Les infections vibrioniques peuvent-elles être asymptomatiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent être asymptomatiques, surtout chez les porteurs sains." } }, { "@type": "Question", "name": "Comment prévenir les infections par Vibrionaceae ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par une bonne hygiène, la cuisson des aliments et l'eau potable." } }, { "@type": "Question", "name": "Les vaccins existent-ils contre Vibrionaceae ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un vaccin contre le choléra est disponible, mais pas pour toutes les espèces de Vibrionaceae." } }, { "@type": "Question", "name": "Quelles mesures de sécurité alimentaire sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de bien cuire les fruits de mer et de ne pas consommer d'eau non traitée." } }, { "@type": "Question", "name": "Les voyageurs doivent-ils prendre des précautions ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyageurs vers des zones à risque doivent être prudents avec l'eau et la nourriture." } }, { "@type": "Question", "name": "L'hygiène des mains est-elle importante ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, se laver les mains régulièrement est crucial pour prévenir les infections." } }, { "@type": "Question", "name": "Quel est le traitement principal pour les infections par Vibrionaceae ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "La réhydratation orale ou intraveineuse est le traitement principal, surtout pour le choléra." } }, { "@type": "Question", "name": "Les antibiotiques sont-ils nécessaires pour traiter Vibrionaceae ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les antibiotiques peuvent être prescrits dans les cas graves, mais ne sont pas toujours nécessaires." } }, { "@type": "Question", "name": "Comment prévenir la déshydratation dans les infections vibrioniques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'administration rapide de solutions de réhydratation est essentielle pour prévenir la déshydratation." } }, { "@type": "Question", "name": "Les traitements symptomatiques sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements symptomatiques comme les antiémétiques peuvent aider à soulager les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des traitements spécifiques pour le choléra ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antibiotiques spécifiques et des solutions de réhydratation sont recommandés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Vibrionaceae ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent la déshydratation sévère, le choc et l'insuffisance rénale." } }, { "@type": "Question", "name": "Le choléra peut-il entraîner des complications graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le choléra peut entraîner des complications graves comme le choc hypovolémique." } }, { "@type": "Question", "name": "Les infections vibrioniques peuvent-elles être mortelles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement approprié, les infections peuvent être mortelles, surtout chez les vulnérables." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont gérées par une réhydratation rapide et un traitement médical approprié." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque de complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées sont plus susceptibles de développer des complications graves." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'eau contaminée." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées courent un risque accru d'infections graves." } }, { "@type": "Question", "name": "Le climat influence-t-il le risque d'infection ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections par Vibrionaceae sont plus fréquentes dans les climats chauds et humides." } }, { "@type": "Question", "name": "Les enfants sont-ils plus vulnérables ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les enfants peuvent être plus vulnérables aux infections et à leurs complications." } }, { "@type": "Question", "name": "Les voyages dans certaines régions augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des régions à risque augmente la probabilité d'infection par Vibrionaceae." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 14/03/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Chunqi Jiang

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Microbiology, Faculty of Fisheries Sciences, Hokkaido University, Hakodate, Japan.

Sayaka Mino

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Microbiology, Faculty of Fisheries Sciences, Hokkaido University, Hakodate, Japan.

Jesús L Romalde

2 publications dans cette catégorie

Affiliations :
  • Departamento de Microbiología y Parasitología, CRETUS & CIBUS-Facultad de Biología, Universidade de Santiago de Compostela, Campus Vida, Santiago de Compostela, España.

Tomoo Sawabe

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Microbiology, Faculty of Fisheries Sciences, Hokkaido University, Hakodate, Japan. sawabe@fish.hokudai.ac.jp.

William Soto

1 publication dans cette catégorie

Affiliations :
  • Integrated Science Center Rm 3035, Department of Biology, College of William & Mary, 540 Landrum Dr., Williamsburg, VA 23185, USA.
Publications dans "Vibrionaceae" :

Nurliyana Mohamad

1 publication dans cette catégorie

Affiliations :
  • Department of Biology, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Publications dans "Vibrionaceae" :

Muskhazli Mustafa

1 publication dans cette catégorie

Affiliations :
  • Department of Biology, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Publications dans "Vibrionaceae" :

Mohammad Noor Azmai Amal

1 publication dans cette catégorie

Affiliations :
  • Department of Biology, Faculty of Science, Universiti Putra Malaysia, and Laboratory of Marine Biotechnology, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Publications dans "Vibrionaceae" :

Mohd Zamri Saad

1 publication dans cette catégorie

Affiliations :
  • Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia, and Laboratory of Marine Biotechnology, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Publications dans "Vibrionaceae" :

Ina Salwany Md Yasin

1 publication dans cette catégorie

Affiliations :
  • Department of Aquaculture, Faculty of Agriculture, Universiti Putra Malaysia, and Laboratory of Marine Biotechnology, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Publications dans "Vibrionaceae" :

Nurhidayu Al-Saari

1 publication dans cette catégorie

Affiliations :
  • Laboratory of Marine Biotechnology, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
  • International Institute for Halal Research and Training, International Islamic University Malaysia, 53100 Gombak, Selangor, Malaysia.
Publications dans "Vibrionaceae" :

Paula Blanco

1 publication dans cette catégorie

Affiliations :
  • Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid 28040, Spain.
  • VISAVET Health Surveillance Centre, Universidad Complutense de Madrid, Madrid 28040, Spain.
Publications dans "Vibrionaceae" :

Alberto Hipólito

1 publication dans cette catégorie

Affiliations :
  • Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid 28040, Spain.
  • VISAVET Health Surveillance Centre, Universidad Complutense de Madrid, Madrid 28040, Spain.
Publications dans "Vibrionaceae" :

Lucía García-Pastor

1 publication dans cette catégorie

Affiliations :
  • Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid 28040, Spain.
  • VISAVET Health Surveillance Centre, Universidad Complutense de Madrid, Madrid 28040, Spain.
Publications dans "Vibrionaceae" :

Filipa Trigo da Roza

1 publication dans cette catégorie

Affiliations :
  • Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid 28040, Spain.
  • VISAVET Health Surveillance Centre, Universidad Complutense de Madrid, Madrid 28040, Spain.
Publications dans "Vibrionaceae" :

Laura Toribio-Celestino

1 publication dans cette catégorie

Affiliations :
  • Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid 28049, Spain.
Publications dans "Vibrionaceae" :

Alba Cristina Ortega

1 publication dans cette catégorie

Affiliations :
  • Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid 28040, Spain.
Publications dans "Vibrionaceae" :

Ester Vergara

1 publication dans cette catégorie

Affiliations :
  • Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid 28040, Spain.
  • VISAVET Health Surveillance Centre, Universidad Complutense de Madrid, Madrid 28040, Spain.
Publications dans "Vibrionaceae" :

Álvaro San Millán

1 publication dans cette catégorie

Affiliations :
  • Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid 28049, Spain.
  • Centro de Investigación Biológica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid 28222, Spain.
Publications dans "Vibrionaceae" :

José Antonio Escudero

1 publication dans cette catégorie

Affiliations :
  • Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid 28040, Spain.
  • VISAVET Health Surveillance Centre, Universidad Complutense de Madrid, Madrid 28040, Spain.
Publications dans "Vibrionaceae" :

Sources (10000 au total)

Predictors of Cessation in Men Using a Tobacco Quitline: A Follow-Up Study.

Although the effectiveness of tobacco quitline services for people who smoke cigarettes is well established, less is known about other forms of tobacco. This study aimed to compare quit rates and fact... Self-reported 30-day point-prevalence tobacco abstinence at the 7-month follow-up was calculated in males who registered with the Oklahoma Tobacco Helpline and completed a 7-month follow-up survey (N=... Abstinence was reported by 33% in the dual-use group, 46% in the smokeless-tobacco-use-only group, and 32% in the cigarette-use-only group. Eight or more weeks of nicotine replacement therapy provided... Men in all three tobacco-use groups who fully utilized quitline services showed a greater likelihood of tobacco abstinence. These findings underscore the importance of quitline intervention as an evid...

Smoking cessation patterns, usefulness of quitting methods, and tobacco cessation motivators and barriers to quit in patients with rheumatoid arthritis.

Tobacco use is highly discouraged in patients with rheumatoid arthritis (RA) due to related short and long-term health implications. We aimed to evaluate smoking cessation patterns in patients with RA... We surveyed adults with RA enrolled in the FORWARD Databank who self-identified as former or current tobacco users.... Three hundred forty-eight participants completed the survey and responded to the question "do you currently smoke" (former use = 319; current use = 29). Nicotine replacement therapy (NRT) was perceive... Current users expressed several negative emotions including coping with the disease and "being a pleasurable habit" when trying to quit. Future cessation programs should address these barriers to supp...

A Clinical Decision Support System for Motivational Messaging and Tobacco Cessation Treatment for Parents: Pilot Evaluation of Use and Acceptance.

Research is needed to identify how clinical decision support (CDS) systems can support communication about and engagement with tobacco use treatment in pediatric settings for parents who smoke. We dev... The objective of this study is to assess the performance of this system in clinical practice, including receipt of motivational messages and tobacco use treatment acceptance rates.... The system was evaluated at one large pediatric practice through a single-arm pilot study from June to November 2021. We collected data on the performance of the CDS system for all parents. Additional... During the entire study period, 8,488 parents completed use of the CDS: 9.3% (... A CDS system to support parental tobacco use treatment in pediatric primary care enhanced motivational messaging about smoking cessation and evidence-based treatment initiation....

Economic Evaluation of Enhanced vs Standard Varenicline Treatment for Tobacco Cessation.

Smoking is the leading preventable cause of death and illness in the US. Identifying cost-effective smoking cessation treatment may increase the likelihood that health systems deliver such treatment t... To evaluate the cost-effectiveness of standard vs enhanced varenicline use (extended varenicline treatment or varenicline in combination with nicotine replacement therapy) among individuals trying to ... This economic evaluation assesses the Quitting Using Intensive Treatments Study (QUITS), which randomized 1251 study participants who smoked into 4 conditions: (1) 12-week varenicline monotherapy (n =... The primary outcome was 7-day point prevalence abstinence (biochemically confirmed with exhaled carbon monoxide level ≤5 ppm) at 52 weeks. The incremental cost-effectiveness ratio (ICER), or cost per ... Of the 1251 participants, mean (SD) age was 49.1 (11.9) years, 675 (54.0%) were women, and 881 (70.4%) completed the 52-week follow-up. Tobacco cessation at 52 weeks was 25.1% (79 of 315) for 12-week ... This economic evaluation of standard vs enhanced varenicline treatment for smoking cessation suggests that 12-week varenicline monotherapy was the most cost-effective treatment option at the commonly ...

Understanding Hesitation to Use Nicotine Replacement Therapy: A Content Analysis of Posts in Online Tobacco-Cessation Support Groups.

We aimed to better understand hesitancy to use nicotine replacement therapy (NRT) to quit smoking.... We content coded and analyzed NRT-related posts in online quit smoking support groups to understand NRT-use hesitancy and to examine associations with health outcomes.... NRT posts were analyzed in unmoderated social-media support groups with free NRT.... Adults who smoked daily (n = 438) and posted about NRT were studied, 339 of whom reported on NRT usage and 403 reported on smoking abstinence.... Surveys at 1-month post-quit date assessed NRT usage and smoking abstinence.... Relationships among NRT posts, NRT usage and smoking abstinence were analyzed using GEE models accounting for support group and covariates.... Nearly all (96.17%) participants reported using the study-provided NRT once, most (70.21%) used NRT during the past week, but less than half (45.72%) used NRT daily for the full month as recommended. ... Strategies are needed to address dislike of NRT and strengthen perceptions of NRT efficacy, especially on social media where posts may be amplified....

Assessing and minimizing risk of bias in randomized controlled trials of tobacco cessation interventions: Guidance from the Cochrane Tobacco Addiction Group.

The Cochrane Tobacco Addiction Group has created risk of bias tools, which are topic-agnostic. In 2012 the Cochrane Tobacco Addiction Group created guidance specific to considerations for reviews of r...

Impact of a Multidisciplinary Curriculum Training Students and Residents in Tobacco Cessation Strategies for Adult Caregivers of Children.

Children's exposure to secondhand smoke is an underaddressed public health threat. The Clinical Effort Against Secondhand Smoke Exposure (CEASE) is a validated framework that trains pediatric provider... A physician champion at a major urban academic center delivered a longitudinal didactic curriculum of CEASE principles to medical and nurse practitioner students and pediatrics and family medicine res... Fifty-two trainees (55% students, 45% residents) responded to the evaluation survey administered immediately following training. There were statistically significant improvements in median scores afte... CEASE training successfully improved the self-efficacy of health professions students and residents in smoking cessation techniques for adult caregivers of children....

Smoking Cessation Pharmacotherapy Use in Pregnancy.

Significant evidence gaps exist regarding the safety of smoking cessation pharmacotherapies during pregnancy, especially for the risk of congenital malformations. Consequently, professional bodies adv... To quantify the proportion of individuals using prescribed smoking cessation pharmacotherapies during pregnancy and during the first trimester specifically, in 4 countries.... This retrospective, population-based cohort study used linked birth records, hospital admission records, and dispensing records of prescribed medications from all pregnancies resulting in birth betwee... Prescribed smoking cessation pharmacotherapy use (varenicline, NRT, and bupropion) during pregnancy was defined as days' supply overlapping the period from date of conception to childbirth.... Prevalence of use among all pregnancies and pregnancies with maternal smoking were calculated. Among women who used a pharmacotherapy, the proportion of women with use during the first trimester of pr... Among 1 700 638 pregnancies in 4 countries, 138 033 (8.1%) had maternal smoking and 729 498 (42.9%) were younger than 30 years. The prevalences ranged from 0.02% to 0.14% for varenicline, less than 0.... In this cohort study of pregnant individuals in 4 high-income countries, the low prevalence of varenicline and bupropion use during pregnancy and higher prevalence of NRT use aligned with current clin...